Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2021 | Story ANDRÉ DAMONS | Photo ANDRÉ DAMONS
Dr Osayande Evbuomwan, a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, always wanted to specialise in an area of medicine that was novel, innovative, intriguing and involved a lot of opportunities for groundbreaking research

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS) always wanted to specialize in an area of medicine that was novel, innovative, intriguing and involved many opportunities for groundbreaking research.

This passionate medical man, who joined the UFS in 2019, is behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer. 
The UFS and the Free State province can now join other South African universities, like the University of Pretoria, University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients. 

Built for this job

Dr Evbuomwan explains nuclear medicine is a medical specialty that involves the use of unsealed sources of radiation in the form of radioisotopes for the diagnosis and treatment of various disease conditions including cancers.
“It’s novelty and opportunity for research and ability to diagnose and treat disease conditions in one specialty attracted me to this field. I always wanted to be a doctor. I see it as a calling. It was also something my mum discovered while I was growing up as a child. In my next life, I would choose to be a medical doctor again,” he says.

“I was built for this job and it is always my joy to have the opportunity to carry out my work. We have been well-trained for this; we support all our skills with prayers. We try to give our patients the very best,” says Dr Evbuomwan, who is originally from Benin City, Edo state, Nigeria. 

After graduating as a nuclear medicine specialist from Wits University, Dr Evbuomwan moved to the City of Roses after a work opportunity opened. He saw it as an opportunity to showcase his talents.

“I have been privileged to receive training in this treatment during my residency training at Wits. I treated a few of these patients during my training and the results were amazing. The University of Pretoria has also been involved with this treatment, with some amazing results that are recognised worldwide. 

“This was enough to convince me to push for our department to also join the powerhouses and offer this treatment to patients who need it. With the influence of a very understanding head of department, Dr Gerrit Engelbrecht, we have been successful in pushing for the commencement of this treatment at our facility,” says Dr Evbuomwan.

Important treatment
According to him, the availability and expertise of Lutetium 177 PSMA (Lu-177 PSMA) therapy to treat MCRPC is very important for the Free State and the UFS, as it is able to offer an option for patients who do not qualify for available conventional treatment and/or who have failed the first line of conventional treatment. 

“In the majority of patients this treatment offers improved quality of life, disease-free progression and improved overall survival. It also alleviates the constant bone pains these patients have to go through daily. To be able to offer this treatment puts the university and the province on the map alongside other top institutions in and outside the country. It also offers opportunity for research,” says Dr Evbuomwan.

He believes with a PET/CT camera for proper staging of these patients with cancer the UFS would be able to expand the treatment of patients suffering from this deadly illness. Currently the university does not possess such a camera and has to use lesser methods in identifying the right patients for this therapy.

News Archive

UFS to host one of three world summits on crystallography
2014-04-15

 
Prof André Roodt from the Department of Chemistry at the University of the Free State (UFS), co-unveiled a special plaque in Poznan, Poland, as president of the European Crystallographic Association, with prof Gautam Desiraju, president of the IUCr (front right) and others to commemorate the Nobel prize winner Max von Laue. (Photo's: Milosz Ruszkowski, Grzegorz Dutkiewicz)

Prof André Roodt from the Department of Chemistry at the University of the Free State (UFS), co-unveiled a special plaque in Poznan, Poland, as president of the European Crystallographic Association, to commemorate the Nobel prize winner Max von Laue at a special Laue Symposium organised by prof Mariusz Jaskolski from the A. Mickiewicz University in Poznan.

Max von Laue, who spent his early childhood in Poznan, was the first scientist to diffract X-rays with a crystal.

2014 has been declared by the United Nations as the International Year of Crystallography, and it was recently officially opened at the UNESCO headquarters in Paris, France, by the Secretary-General of the UN, Ban Ki-moon. The International Year of Crystallography celebrates the centennial of the work of Max von Laue and the father and son, William Henry and William Laurence Bragg.

As part of the celebrations, Prof Roodt, president of the European Crystallographic Association, one of the three regional affiliates (Americas, Europe and Africa; Asia and Australasia) of the International Union of Crystallography (IUCr), was invited by the president of the IUCr, Prof Gautam Desiraju, to host one of the three world summits, wherein crystallography is to showcase its achievements and strategise for the future.

The summit and conference will take place on the Bloemfontein Campus of the UFS from 12 to 17 October 2014 and is titled: 'Crystallography as vehicle to promote science in Africa and beyond.' It is an ambitious meeting wherein it is anticipated to bring the French-, English- and Arab-speaking nations of Africa together to strategise how science can be expanded, and to offer possibilities for this as nestled in crystallography. Young and established scientists, and politicians associated with science and science management, are the target audience to be brought together in Bloemfontein.

Dr Thomas Auf der Heyde, acting Director General of the South African Department of Science and Technology (DST), has committed some R500 000 for this effort, while the International Union of Crystallography provided R170 000.

“Crystals and crystallography form an integrated part of our daily lives, form bones and teeth, to medicines and viruses, new catalysts, jewellery, colour pigments, chocolates, electronics, batteries, metal blades in airplane turbines, panels for solar energy and many more. In spite of this, unfortunately, not many people know much about X-ray crystallography, although it is probably one of the greatest innovations of the twentieth century. Determining the structure of the DNA was one of the most significant scientific events of the 20th century. It has helped understand how genetic messages are being passed on between cells inside our body – everything from the way instructions are sent to proteins to fight infections, to how life is reproduced.

“At the UFS, crystallography finds application in Chemistry, Physics, Biology, Mathematics, Geology, Engineering and the Medical fields. Crystallography is used by the Curiosity Rover, analysing the substances and minerals on Mars!

“The UFS’s Departments of Chemistry and Physics, in particular, have advanced instruments and important research thrusts wherein X-ray crystallography has formed a central part for more than 40 years.

“Crystallography has produced some 28 Nobel prize winners over the past 100 years and continues to provide the means for fundamental and applied research,” said Prof Roodt.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept